Effect of continuation of antiplatelet therapy on survival in patients receiving physician home visits

Yasuhiro Osugi, Teruo Ino, Daiki Kobayashi, Mitsunaga Iwata, Kanichi Asai

Research output: Contribution to journalArticle

Abstract

Background: Little is known about the effects of continued antiplatelet therapy in patients who receive physician home visits. This study aimed to evaluate the association of survival with the continuation of antiplatelet drugs in patients who received physician home visits. Methods: A retrospective cohort study was conducted in a teaching hospital in Toyota, Japan, from April 2015 to October 2018. All patients who received home visits by physicians from the department of Family Medicine of the hospital were included. The primary outcome was the difference in all-cause mortality between patients who were taking antiplatelet drugs and those who were not. The Cox proportional hazards model was applied, adjusted for the patient's demographic features, activities of daily living, comorbidities, and primary disease requiring home care. Results: A total of 815 patients were included, of whom 61 received antiplatelet drugs (n = 42 for aspirin, n = 17 for clopidogrel, and n = 8 for cilostazol) and 772 received no antiplatelet drugs. The mean age of the patients was 78.3 years, 409 (49.1%) were male, and 314 (37.7%) had end-stage cancer. During a median follow-up period of 120 days (interquartile range, 29-364), 54.3% of the patients died. Compared with patients not taking antiplatelet drugs, patients taking antiplatelet drugs had a better outcome (p < 0.01, log-rank test) and a significantly lower hazard ratio (0.34; 95% confidence interval, 0.17-0.65; Cox proportional hazards regression). Conclusions: The continuous prescription of antiplatelet drugs may have beneficial effects on mortality among patients who receive physician home visits.

Original languageEnglish
Article number366
JournalBMC Geriatrics
Volume19
Issue number1
DOIs
Publication statusPublished - 23-12-2019

Fingerprint

House Calls
Platelet Aggregation Inhibitors
Physicians
Survival
Therapeutics
clopidogrel
Hospital Medicine
Prescription Drugs
Mortality
Family Physicians
Home Care Services
Activities of Daily Living
Proportional Hazards Models
Teaching Hospitals
Aspirin
Comorbidity
Japan
Cohort Studies
Retrospective Studies
Demography

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology

Cite this

Osugi, Yasuhiro ; Ino, Teruo ; Kobayashi, Daiki ; Iwata, Mitsunaga ; Asai, Kanichi. / Effect of continuation of antiplatelet therapy on survival in patients receiving physician home visits. In: BMC Geriatrics. 2019 ; Vol. 19, No. 1.
@article{e511e0a74c7d4357b708adc9cb9c97b8,
title = "Effect of continuation of antiplatelet therapy on survival in patients receiving physician home visits",
abstract = "Background: Little is known about the effects of continued antiplatelet therapy in patients who receive physician home visits. This study aimed to evaluate the association of survival with the continuation of antiplatelet drugs in patients who received physician home visits. Methods: A retrospective cohort study was conducted in a teaching hospital in Toyota, Japan, from April 2015 to October 2018. All patients who received home visits by physicians from the department of Family Medicine of the hospital were included. The primary outcome was the difference in all-cause mortality between patients who were taking antiplatelet drugs and those who were not. The Cox proportional hazards model was applied, adjusted for the patient's demographic features, activities of daily living, comorbidities, and primary disease requiring home care. Results: A total of 815 patients were included, of whom 61 received antiplatelet drugs (n = 42 for aspirin, n = 17 for clopidogrel, and n = 8 for cilostazol) and 772 received no antiplatelet drugs. The mean age of the patients was 78.3 years, 409 (49.1{\%}) were male, and 314 (37.7{\%}) had end-stage cancer. During a median follow-up period of 120 days (interquartile range, 29-364), 54.3{\%} of the patients died. Compared with patients not taking antiplatelet drugs, patients taking antiplatelet drugs had a better outcome (p < 0.01, log-rank test) and a significantly lower hazard ratio (0.34; 95{\%} confidence interval, 0.17-0.65; Cox proportional hazards regression). Conclusions: The continuous prescription of antiplatelet drugs may have beneficial effects on mortality among patients who receive physician home visits.",
author = "Yasuhiro Osugi and Teruo Ino and Daiki Kobayashi and Mitsunaga Iwata and Kanichi Asai",
year = "2019",
month = "12",
day = "23",
doi = "10.1186/s12877-019-1394-6",
language = "English",
volume = "19",
journal = "BMC Geriatrics",
issn = "1471-2318",
publisher = "BioMed Central",
number = "1",

}

Effect of continuation of antiplatelet therapy on survival in patients receiving physician home visits. / Osugi, Yasuhiro; Ino, Teruo; Kobayashi, Daiki; Iwata, Mitsunaga; Asai, Kanichi.

In: BMC Geriatrics, Vol. 19, No. 1, 366, 23.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of continuation of antiplatelet therapy on survival in patients receiving physician home visits

AU - Osugi, Yasuhiro

AU - Ino, Teruo

AU - Kobayashi, Daiki

AU - Iwata, Mitsunaga

AU - Asai, Kanichi

PY - 2019/12/23

Y1 - 2019/12/23

N2 - Background: Little is known about the effects of continued antiplatelet therapy in patients who receive physician home visits. This study aimed to evaluate the association of survival with the continuation of antiplatelet drugs in patients who received physician home visits. Methods: A retrospective cohort study was conducted in a teaching hospital in Toyota, Japan, from April 2015 to October 2018. All patients who received home visits by physicians from the department of Family Medicine of the hospital were included. The primary outcome was the difference in all-cause mortality between patients who were taking antiplatelet drugs and those who were not. The Cox proportional hazards model was applied, adjusted for the patient's demographic features, activities of daily living, comorbidities, and primary disease requiring home care. Results: A total of 815 patients were included, of whom 61 received antiplatelet drugs (n = 42 for aspirin, n = 17 for clopidogrel, and n = 8 for cilostazol) and 772 received no antiplatelet drugs. The mean age of the patients was 78.3 years, 409 (49.1%) were male, and 314 (37.7%) had end-stage cancer. During a median follow-up period of 120 days (interquartile range, 29-364), 54.3% of the patients died. Compared with patients not taking antiplatelet drugs, patients taking antiplatelet drugs had a better outcome (p < 0.01, log-rank test) and a significantly lower hazard ratio (0.34; 95% confidence interval, 0.17-0.65; Cox proportional hazards regression). Conclusions: The continuous prescription of antiplatelet drugs may have beneficial effects on mortality among patients who receive physician home visits.

AB - Background: Little is known about the effects of continued antiplatelet therapy in patients who receive physician home visits. This study aimed to evaluate the association of survival with the continuation of antiplatelet drugs in patients who received physician home visits. Methods: A retrospective cohort study was conducted in a teaching hospital in Toyota, Japan, from April 2015 to October 2018. All patients who received home visits by physicians from the department of Family Medicine of the hospital were included. The primary outcome was the difference in all-cause mortality between patients who were taking antiplatelet drugs and those who were not. The Cox proportional hazards model was applied, adjusted for the patient's demographic features, activities of daily living, comorbidities, and primary disease requiring home care. Results: A total of 815 patients were included, of whom 61 received antiplatelet drugs (n = 42 for aspirin, n = 17 for clopidogrel, and n = 8 for cilostazol) and 772 received no antiplatelet drugs. The mean age of the patients was 78.3 years, 409 (49.1%) were male, and 314 (37.7%) had end-stage cancer. During a median follow-up period of 120 days (interquartile range, 29-364), 54.3% of the patients died. Compared with patients not taking antiplatelet drugs, patients taking antiplatelet drugs had a better outcome (p < 0.01, log-rank test) and a significantly lower hazard ratio (0.34; 95% confidence interval, 0.17-0.65; Cox proportional hazards regression). Conclusions: The continuous prescription of antiplatelet drugs may have beneficial effects on mortality among patients who receive physician home visits.

UR - http://www.scopus.com/inward/record.url?scp=85077131582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077131582&partnerID=8YFLogxK

U2 - 10.1186/s12877-019-1394-6

DO - 10.1186/s12877-019-1394-6

M3 - Article

C2 - 31870311

AN - SCOPUS:85077131582

VL - 19

JO - BMC Geriatrics

JF - BMC Geriatrics

SN - 1471-2318

IS - 1

M1 - 366

ER -